Citius Pharmaceuticals
CTXR
73 hedge funds and large institutions have $87.4M invested in Citius Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 43 funds opening new positions, 18 increasing their positions, 6 reducing their positions, and 9 closing their positions.
378% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 9
352% more capital invested
Capital invested by funds: $19.3M → $87.4M (+$68.1M)
200% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 6
154% more call options, than puts
Call options by funds: $295K | Put options by funds: $116K
87% more funds holding
Funds holding: 39 → 73 (+34)
0.42% more ownership
Funds ownership: 0.33% → 0.74% (+0.42%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$14.9M |
| 2 |
State Street
Boston,
Massachusetts
|
+$4.73M |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$2.59M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.53M |
| 5 |
Renaissance Technologies
New York
|
+$2.19M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$559K |
| 2 |
Millennium Management
New York
|
-$299K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$158K |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$123K |
| 5 |
LP
LMR Partners
London,
United Kingdom
|
-$114K |
CTXR Hedge Fund Activity: Q2 2021 in Review
73 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Citius Pharmaceuticals (CTXR) for Q2 2021, worth a combined $87.4M — up 352% from $19.3M a quarter earlier.
Buyers outnumbered sellers: 43 funds opened new CTXR positions and 9 closed out — a net gain of 34 holders — while 18 added to existing stakes and 6 trimmed.
The largest buyer was BlackRock, adding an estimated $14.9M. The largest seller was Sabby Management, exiting entirely with an estimated $559K sold.
- 73 institutional investors held Citius Pharmaceuticals (CTXR) as of Q2 2021, up from 39 in Q1 2021.
- Funds reported $87.4M of Citius Pharmaceuticals stock for Q2 2021, up 352% quarter-over-quarter.
- 43 funds opened new Citius Pharmaceuticals positions in Q2 2021 and 9 closed out, a net change of +34 holders.
- The largest Citius Pharmaceuticals buyer in Q2 2021 was BlackRock, an estimated $14.9M added.
- The largest Citius Pharmaceuticals seller in Q2 2021 was Sabby Management, an estimated $559K sold.
Based on aggregated 13F filings for Q2 2021.